Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting

• DOI: 10.18632/oncotarget.16982
• Publication Date: 2017-04-09T18:47:13Z
• Authors: Laura Pizzuti; Clara Natoli; Teresa Gamucci; Mariella Mauri; Domenico Sergi; Luigi Di Lauro; Giancarlo Paoletti; Enzo Ruggeri; Laura Iezzi; Isabella Sperduti; Lucia Mentuccia; Agnese Fabbri; Marcello Maugeri-...; Luca Moscetti; Maddalena Barba; Patrizia Vici
• Keywords: Fulvestrant

To characterize determinants of treatment outcome in a real world population 161 post-menopausal hormone receptor-positive metastatic breast cancer patients treated with fulvestrant. Descriptive statistics for demographics, anthropometrics, clinical and molecular characteristic were compared across subgroups sensitivity/resistance to prior endocrine therapy tested uni/multivariate models. Clinical benefit was more common sensitive higher estrogen receptor expression when fulvestrant given first line (p=0.02 0.046). In resistant patients, PFS longer lower BMI (p=0.01). Among women, associated first-line, single metastasis no visceral involvement (p=0.01, 0.003 0.01). OS shorter HER2-positive disease if second subsequent (p=0.03). we observed worse multiple metastases (p=0.008). Multivariate analyses confirmed older age (p=0.002 0.007). negatively influenced by HER2 positivity (p=0.04). poorer survival (p=0.002). This evidence encourages considering patient characteristics decision making interpretation candidate